Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial-Reference-Cited by-同舟云学术

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

Published:2014-11 Issue:12 Volume:15 Page:1397-1406
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hoskin Peter,Sartor Oliver,O'Sullivan Joe M,Johannessen Dag Clement,Helle Svein I,Logue John,Bottomley David,Nilsson Sten,Vogelzang Nicholas J,Fang Fang,Wahba Mona,Aksnes Anne-Kirsti,Parker Christopher

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Clinical practice guidelines in oncology—prostate cancer (version 2.2014),2014

4. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity;Schutz;Crit Rev Oncol Hematol,2014

5. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population;Engel-Nitz;Cancer Manag Res,2011

Cited by 357 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative single-photon emission computed tomography/computed tomography in assessing the effectiveness of radium-223 dichloride therapy;Cancer Urology;2024-08-15

2. Symptom burden among men treated for castration-resistant prostate cancer: a longitudinal study;BMJ Supportive & Palliative Care;2024-08-08

3. Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2024-06-26

4. Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study;International Journal of Cancer;2024-06-26

5. Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer;Cancers;2024-04-15